Trends in CIDP drug development focus on reducing treatment frequency, minimizing side effects, and enhancing nerve repair, with several promising candidates in late-stage clinical trials. https://www.marketresearchfuture.com/reports/chronic-inflammatory-demyelinating-polyneuropathy-market-6947